Shopping Cart
- Remove All
Your shopping cart is currently empty
Anti-GM-CSF/CSF2 Antibody-HRP (2Z919)
😃Good
Catalog No. TMAY-00084H
Alias GM-CSF, GMCSF, CSF2, colony stimulating factor 2 (granulocyte-macrophage)
Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) is a HRP-conjugated Mouse antibody targeting GM-CSF/CSF2. Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) can be used in ELISA.
Anti-GM-CSF/CSF2 Antibody-HRP (2Z919)
Anti-GM-CSF/CSF2 Antibody-HRP (2Z919)
😃Good
Catalog No. TMAY-00084HAlias GM-CSF, GMCSF, CSF2, colony stimulating factor 2 (granulocyte-macrophage)
Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) is a HRP-conjugated Mouse antibody targeting GM-CSF/CSF2. Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) can be used in ELISA.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 μg | $293 | 7-10 days |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
| Description | Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) is a HRP-conjugated Mouse antibody targeting GM-CSF/CSF2. Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) can be used in ELISA. |
| Alias | GM-CSF, GMCSF, CSF2, colony stimulating factor 2 (granulocyte-macrophage) |
| Ig Type | Monoclonal Mouse IgG1 |
| Clone | 2Z919 |
| Reactivity | Human |
| Application | ELISA |
| Recommended Dose | ELISA: 0.1-1 μg/ml |
| Antibody Type | Monoclonal |
| Host Species | Mouse |
| Construction | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human GM-CSF / CSF2 (rh GM-CSF / CSF2; TMPY-02466; NP_000749.2; Ala 18-Glu 144). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography and conjugated with horseradish-peroxidase (HRP). |
| Purification | Protein A |
| Appearance | Liquid |
| Formulation | 0.2 μm filtered solution in PBS |
| Research Background | Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
| Conjucates | HRP |
| Others Formats | Unconjugated |
| Antibody Types Available | 2 |
| Immunogen | Recombinant Human GM-CSF / CSF2 protein (TMPY-02466) |
| Antigen Species | Human |
| Biology Area | Cancer Drug Targets |
Stability & Storage
| Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. Keep away from direct sunlight. |
| Transport | Shipping with blue ice. |
Sci Citations
Calculator
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . 
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) | purchase Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) | Anti-GM-CSF/CSF2 Antibody-HRP (2Z919) cost | order Anti-GM-CSF/CSF2 Antibody-HRP (2Z919)
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.